NCT02360917 (Haze) is a NA clinical trial of Emerging from the Haze in Cognition, sponsored by Cedars-Sinai Medical Center.

Who is sponsoring NCT02360917?

NCT02360917 is sponsored by Cedars-Sinai Medical Center.

What drugs are being tested in NCT02360917?

Interventions in NCT02360917: Emerging from the Haze.

What condition does NCT02360917 study?

NCT02360917 studies Cognition, Cancer.

Is NCT02360917 still recruiting?

NCT02360917 is currently completed. Last updated 1 November 2018.

Last reviewed 2018-11-01 · How we verify

NCT02360917: Haze

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Emerging From the Haze™- Measuring the Impact of a Psycho-education Program on Perceived Cognition After Breast Cancer Treatment

Completed NA Last updated 1 November 2018

What this trial tests

NA trial testing Emerging from the Haze in Cognition in 31 participants. Completed in 23 May 2018.

Timeline

6 July 2015

Primary endpoint
17 March 2018

23 May 2018

Quick facts

Lead sponsor	Cedars-Sinai Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	31
Start date	6 July 2015
Primary completion	17 March 2018
Estimated completion	23 May 2018
Sites	1 location across United States

Drugs / interventions tested

Emerging from the Haze

Conditions studied

Cognition — all drugs for Cognition →
Cancer — all drugs for Cancer →

Sponsor

Cedars-Sinai Medical Center

Who can join

18 and older, female only, with Cognition or Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

At Cedars-Sinai Medical Center, we have developed a novel curriculum for a 6-week psycho-educationally-based, cognitive behavioral program to help patients with subjective cognitive complaints after cancer treatment, titled Emerging from the Haze™ (Haze). Each series meets once a week for 2 hours for 6 weeks. The leading neuropsychologist covers material such as guided relaxation, behavioral strategies for automatic/negative thoughts, compensatory strategies for attention and memory, executive functioning, pacing, and balance. Each Haze series will be electronically delivered in a live format to our satellite site, The University of Kansas.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Non-pharmacological interventions for cognitive impairment due to systemic cancer treatment.
Treanor CJ, McMenamin UC, O'Neill RF, Cardwell CR, et al · · 2016 · cited 48× · PMID 27529826 · DOI 10.1002/14651858.cd011325.pub2

Verify or expand the search:

Other recruiting trials for Cognition

Currently open trials in the same condition.

NCT07401212 — GUTLINK4KIDS Intervention · NA · recruiting
NCT07109505 — Nutrition to Support Postoperative Recovery · NA · recruiting
NCT07334392 — Impact of a Multicomponent Exercise Program on Cognitive and Functional Outcomes in Patients With Mild Cognitive Impairm · NA · recruiting
NCT07236229 — The Effects of Immersive Virtual Reality in Patients With Grade 1-2 Adhesive Capsulitis · NA · recruiting
NCT07231497 — Cognitive Strategies in Early Psychosis 1 · Phase 3 · recruiting

Other Cedars-Sinai Medical Center trials

Trials by the same sponsor.

NCT06012487 — Correlates and Control of Blood Pressure Variability · Phase 1 · not yet recruiting
NCT07495995 — SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis · Phase 2 · not yet recruiting
NCT07413965 — TAVR vs SAVR in Severe Bicuspid Aortic Stenosis · NA · not yet recruiting
NCT06521021 — CHOICE to AVOID or RESIST · NA · not yet recruiting
NCT07499089 — Together-Breast Cancer Support Platform · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02360917 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cedars-Sinai Medical Center
Last refreshed: 1 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02360917.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing